PCT-49: CLINICAL-HEMATOLOGICAL EVALUATION OF NEOTROFIN IN THE TREATMENT OF ANEMIC PREGNANT WOMAN IN 10 DE OCTUBRE MUNICIPALITY

J Pharm Pharmacogn Res 3(suppl. 1): S141, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Poster

PCT-49: CLINICAL-HEMATOLOGICAL EVALUATION OF NEOTROFIN IN THE TREATMENT OF ANEMIC PREGNANT WOMAN IN 10 DE OCTUBRE MUNICIPALITY

Suárez S1, Aznar E1, Silva N2, Fernández JR2, González M1, Rodríguez S1, Revilla Y1.

1Centro Nacional de Biopreparados (BioCen). Carretera de Beltrán Km 1 ½. Bejucal, Mayabeque, Cuba. E-mail: sidelsi@biocen.cu
2Hospital Docente Materno Infantil 10 de Octubre. Regla número 52 entre Nuestra Señora de la Caridad y Remedios. Reparto Lawton, 10 de Octubre. La Habana. E-mail: hijasgal@infomed.sld.cu

 

Introduction: Anemia by iron deficiency is highly prevalent, especially in pregnant women. Iron salts have been used as conventional therapy, however, its low solubility and high doses used, cause intolerances that can induce failure of treatment. Neotrofin is a new antianemic with natural components produced at the National Center of Bioproduct (BioCen); it is a compound which contains proteins, amino acids and heme iron. The objective of this study was to determine the effectiveness of Neotrofin in the treatment of iron deficiency anemia in pregnant women. Material and Methods: The study was performed in a longitudinal design, single-center, randomized, open-label, hemoglobin value was less than 110 g/L in the detection of pregnancy, attended in consultation on Nutrition at the Maternal and Child Teaching Hospital (Hijas de Galicia) 10 de Octubre. The estimated sample size was 250 patients and the inclusion of these pregnant in the study was conducted randomly, administering doses of three tablets per day of Neotrofin to recovery of hematological parameters. Results: The study demonstrated the high prevalence of anemia in the area, more than 60%. It was found that 56% of patients Neotrofin was effective in improving hemoglobin levels with a number needed to treat of 2. In addition, Neotrofin guaranteed at a high percent the restoring of iron stores as ferritin. Conclusions: The use of Neotrofin as antianemic in pregnant has a high efficiency by making it possible to use as antianemic in this population.

 

Citation Format: Suárez S, Aznar E, Silva N, Fernández JR, González M, Rodríguez S, Revilla Y (2015) Clinical-hematological evaluation of Neotrofin in the treatment of anemic pregnant woman in 10 de Octubre municipality. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S141. Abstract nr PCT-49.